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Abstract 
Background: Alzheimer’s disease (AD) is the sixth leading cause of death and the most costly disease in the US. 
Despite the enormous impact of AD, there are no treatments that delay onset or stop disease progression currently 
on the market. This is partly due to the complexity of the disease and the largely unknown pathogenesis of sporadic 
AD, which accounts for the vast majority of cases. Epigenetics has been implicated as a critical component to AD 
pathology and a potential “hot spot” for treatments. Histone post-translational modifications (PTMs) are a key ele-
ment in epigenetic regulation of gene expression and are known to be associated with the pathology of numerous 
diseases. Investigation of histone PTMs can help elucidate AD pathology and identify targets for therapies.
Results: A multiple reaction monitoring mass spectrometry assay was used to measure changes in abundance of 
several histone PTMs in frontal cortex from human donors affected with AD (n = 6) and age-matched, normal donors 
(n = 6). Of the changes observed, notable decreases in methylation of H2B residue K108 by 25 % and H4 residue R55 
by 35 % were measured and are likely associated with hydrogen bonding networks important for nucleosome stabil-
ity. Additionally, a 91 % increase in ubiquitination of K120 on H2B was measured as well as an apparent loss in acetyla-
tion of the region near the N-terminus of H4. Our method of quantification was also determined to be precise and 
robust, signifying measured changes were representative of true biological differences between donors and sample 
groups.
Conclusion: We are the first to report changes in methylation of H2B K108, methylation of H4 R55, and ubiquitination 
of H2B K120 in frontal cortex from human donors with AD. These notable PTM changes may be of great importance in 
elucidating the epigenetic mechanism of AD as it relates to disease pathology. Beyond the structural and functional 
impacts of the changes we have measured, the sites of altered PTMs may be used to identify enzymes responsible for 
their modulation, which could be used as prospective drug targets for highly specific AD therapies.
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Background
DNA is packaged into the eukaryotic nucleus as chroma-
tin, a structure comprised of nucleosomes formed by 146 
base pairs of DNA wrapped around an octamer of dupli-
cates of histones H2A, H2B, H3, and H4. These histones 
are dynamically modified by post-translational modifi-
cations (PTMs), known as the “histone code”, which can 
regulate gene expression. Disruption of these PTM codes 
through the use of inhibitors can affect cell cycle, alter 
gene expression, and induce apoptosis [1]. Alzheimer’s 
disease (AD) is the leading neurodegenerative disorder 
and characterized by a global repression of gene expres-
sion. Studies on monozygous twins suggest that AD may 
be caused by epigenetic factors, an explanation for differ-
ent outcomes when the DNA sequence is conserved [2]. 
Once acquired, epigenetic factors, such as DNA meth-
ylation and histone PTMs, can be passed on to offspring 
cells [3]. Common PTMs in histones are acetylation, 
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methylation, phosphorylation, and ubiquitination. His-
tone PTMs are classified into two main mechanisms of 
function: cis and trans. Cis mechanisms modify inter-
actions within and between nucleosomes, while trans 
mechanisms act as signals for other proteins to assist in 
alteration of gene expression, chromatin, or other cellular 
functions [3]. Acetylation of histones is generally char-
acterized by an elevation in gene expression, conversely, 
deacetylation is associated with a decrease in gene 
expression, which is a commonality in AD [4]. Meth-
ylation of arginine and lysine is involved in transcription 
regulation, chromatin remodeling, DNA repair, and sig-
nal transduction [5, 6]. Unlike histone acetyltransferases, 
histone methyltransferases are considerably more site 
specific and often are responsible for modifying only a 
single site on histones. Thus it is important to identify the 
specific sites of histone methylation and their changes 
relevant to pathology. Ubiquitination of histone residues 
has the potential to alter the affinity of histone–histone 
interactions within the nucleosome [7], indicate the pres-
ence of DNA damage [8, 9], and be a marker for other 
functional roles. Phosphorylation can be used to regulate 
mitosis and structural dynamics of nucleosomes. How-
ever, phosphorylation is labile and typically lost during 
the relatively long post-mortem interval in human tissues 
and therefore it is more appropriate to measure phospho-
rylation in animal models when the post-mortem interval 
is a few minutes [10].
In this study, we have identified several sites of histone 
PTMs in frontal cortex from human donors with AD that 
are differentially abundant compared to age-matched 
normal donors. The majority of PTM and protein meas-
urements in AD research are performed in animal mod-
els of neurodegeneration [10, 11], with few studies being 
performed using human brain. While we do not under-
estimate the potential of animal models, measurements 
need to be performed in human brain tissue affected by 
AD to confirm changes are truly indicative of AD pathol-
ogy. With our multiple reaction monitoring (MRM) mass 
spectrometry method of PTM quantification, we were 
able to measure several histone PTMs in frontal cortex 
from humans. Frontal cortex is an ideal neural tissue for 
investigation of PTMs because it is responsible for short-
term memory, cognition, and decision making, which 
are all affected by AD, and it is severely damaged in late 
AD [12]. Significant changes in methylation of H2B K108 
and H4 R55 and ubiquitination of H2B K120 reported 
herein have not been previously reported in frontal cor-
tex from human donors affected with AD. Structural and 
functional effects from these modifications likely have 
implications in AD pathology and may identify enzymes 
associated with these PTMs to be used as drug targets.
Methods
The DC Protein Assay kit was purchased from Bio-Rad 
Laboratories (Hercules, CA, USA). RapiGest SF sur-
factant was from Waters (Milford, MA, USA), Trypsin 
(T0303, Type IX-S from porcine pancreas) and all other 
chemicals were purchased from Sigma-Aldrich (St. 
Louis, MO, USA).
Human tissue
Authors received frozen samples of frontal cortex from 
Washington University School of Medicine Alzheimer’s 
Disease Research Center (St. Louis, MO, USA). Human 
frontal cortex was collected in accordance with guid-
ance from the Washington University Human Research 
Protection Office (HRPO number: 89-0556). The authors 
consulted the Washington University HRPO, which 
determined that Institutional Review Board (IRB) over-
sight was not required for this study and waived the need 
for IRB approval. In the state of Missouri, individuals can 
give prospective consent for autopsy; our participants 
provided this consent by signing the hospital’s autopsy 
form. If the participant does not provide future consent 
before death, the DPOA or next of kin provide it after 
death. Handling of tissues for sample processing con-
formed to University of Maryland regulations. All data 
were analyzed anonymously. Demographic information 
on the de-identified donors is summarized in Additional 
file 1: Table S1.
Purification of histones from frontal cortex for PTM 
screening
To reduce sample complexity for data-dependent screen-
ing for PTMs, histones were purified from tissue. Frontal 
cortex tissue from both AD-affected and normal donors 
were carefully cleaned from white matter and blood and 
1.1  g of cortex was minced. Nuclei isolation and his-
tone purification was performed as previously described 
[13] using nuclei isolation buffer (NIB-250) composed 
of 15  mmol/L Tris–HCl (pH 7.5), 15  mmol/L NaCl, 
60 mmol/L KCl, 5 mmol/L MgCl2, 1 mmol/L CaCl2, and 
250 mmol/L sucrose. Tissue was added to 10 mL of NIB-
250 containing 10  mmol/L DTT, 10  mmol/L sodium 
butyrate, and 0.2 % NP-40 and homogenized on ice with 
a glass/Teflon dounce homogenizer using 10 strokes. 
Homogenate was incubated for 10  min on ice and then 
centrifuged at 1000g for 7 min at 4 °C. Pellet was washed 
with NIB containing 10  mmol/L DTT and 10  mmol/L 
sodium butyrate, but no NP-40. Pellet was supplemented 
with 8 mL 0.4 mol/L H2SO4 and incubated for 2 h at 4 °C 
with rotation. Sample was then centrifuged at 3400g 
for 5 min at 4  °C and resulting supernatant was supple-
mented in a 4:1 (volume ratio) with trichloroacetic acid 
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and allowed to precipitate overnight at 4  °C. Pellet was 
washed with 12 mL of acetone acidified with 0.1 % vol-
ume of hydrochloric acid and centrifuged for 5  min 
at 3400g at 4  °C. Pellet was washed with 12 mL of pure 
acetone and centrifuged for 5 min at 3400g at 4 °C. Pellet 
was air dried for 2 h at room temperature. 1 mL of water 
was added to the pellet and sample was gently rotated to 
allow for histones to be solubilized in the water. Sample 
was then centrifuged for 5  min at 3400g at room tem-
perature and histones were collected in the supernatant. 
Histone concentration was determined using the DC 
protein assay kit and bovine serum albumin as a stand-
ard. Histones were stored at −20  °C before further pro-
cessing. The resulting 100  µL histone sample (15.5  µg) 
was supplemented with 100 µL of 25 mmol/L NH4HCO3 
and 0.1 % (mass fraction) RapiGest SF (Waters, Milford, 
MA, USA) then treated in a 25:1 mass ratio of histone to 
trypsin overnight at 37 °C. Following trypsinolysis, 0.5 % 
trifluoroacetic acid (TFA) was added and incubated at 
37 °C for 1 h to cleave acid-labile RapiGest. Samples were 
then centrifuged at 179,000g for 30 min at 4 °C to remove 
precipitated surfactant. Supernatants were dried using a 
Vacufuge (Eppendorf AG, Hamburg, Germany).
PTM identification and selection
Data-dependent acquisition of histone peptides was per-
formed by LC–MS/MS using an Agilent 6550 QTOF. 
Peptides were eluted from an Agilent ProtID C18 nano-
chip (75 µm × 150 mm, 300 nm) over 120 min gradient 
from 3 to 35  % acetonitrile containing 0.1  % (volume 
fraction) formic acid at a flow rate of 300 nL/min. Acqui-
sition method in positive mode used capillary tempera-
ture 275  °C, fragmentor 180 V, capillary voltage 1950 V, 
a 300–2000 m/z mass window at 8 spectra/s scan rate 
for precursor ions, 1.3  m/z isolation window, and a 
80–1700 m/z mass window at 3 spectra/s scan rate for 
product ions. Collision energy was determined using the 
formula, CE = (3 m/z)/100 + 1, for 2+ charged peptides 
and the formula, CE = (3.6 m/z)/100 − 4.8, for peptides 
3+ charged or greater.
Data was searched against the SwissProt database for 
human proteins using both Mascot (MatrixScience) and 
MassMatrix [14] to identify histone peptides and PTMs. 
Search settings were: precursor mass tolerance, 0.05 Da; 
fragment mass tolerance, 0.05  Da; maximum missed 
cleavages, 4; variable modifications, acetylation of lysine, 
methylation of arginine and lysine, and ubiquitination of 
lysine; enzyme, trypsin. Both Mascot and MassMatrix 
were used in parallel to reduce false positives based on 
inherent differences of individual searching algorithms by 
comparing identifications and their respective retention 
times in both software platforms for a consensus. Identi-
fications in consensus with both Mascot and MassMatrix 
were manually confirmed by spectra annotation. Mass-
Matrix also provides LC retention time analysis, which 
calculates the theoretical retention time and compares 
it the observed retention time and displays a confidence 
score. Retention time confidence scores less than 1  % 
were removed, as recommended by MassMatrix [15]. 
Fragmentation data was then used to develop a transition 
list for MRM (Additional file 2: Table S2).
Human frontal cortex processing for quantitative 
measurements
For quantitative measurements, samples were minimally 
processed (1) to reduce loss of native PTMs and (2) to 
reduce PTM artifacts caused by sample processing. Fron-
tal cortex tissue was carefully cleaned from white matter 
and blood from AD-affected (n = 6) and normal (n = 6) 
donors. Tissue (0.2 g) was minced and then homogenized 
in 1 mL of 25 mmol/L NH4HCO3 by sonication at 50 W 
using four 10  s continuous cycles (Sonicator 3000, Mis-
onix Inc., Farmingdale, NY, USA). Homogenates were 
centrifuged at 2000g for 5 min to remove debris. Result-
ing supernatant was measured for total protein concen-
tration using detergent-compatible DC protein assay kit 
in the presence of 1  % (mass fraction) SDS and bovine 
serum albumin as a standard. Homogenates were stored 
at −80  °C. Samples of 0.2  mg were supplemented with 
20 mmol/L DTT and 1 % (mass fraction) SDS. After 1 h 
incubation at room temperature to reduce cysteines, 
55 mmol/L iodoacetamide was added and incubated for 
an additional 1  h to alkylate cysteines. Protein was iso-
lated by chloroform/methanol precipitation. Protein pel-
lets were sonicated in 1  mL 25  mmol/L NH4HCO3 and 
0.1 % (mass fraction) RapiGest SF and then treated with 
a 25:1 mass ratio of histone to trypsin overnight at 37 °C. 
Following trypsinolysis, 0.5 % TFA was added and incu-
bated at 37 °C for 1 h to cleave acid-labile RapiGest. Sam-
ples were then centrifuged at 179,000g for 30 min at 4 °C 
to remove precipitated surfactant. Supernatants were 
dried using a Vacufuge.
PTM quantification by multiple reaction monitoring
Dried peptides were reconstituted in 3  % acetonitrile, 
97  % water, and 0.1  % formic acid (volume fraction). 
Separation was performed on an Agilent Zorbax Eclipse 
Plus C18 RRHD column (2.1 mm × 50 mm, 1.8 µm par-
ticle) and multiple reaction monitoring (MRM) analysis 
was performed on an Agilent 6490 iFunnel Triple Quad-
rupole LC/MS system (Santa Clara, CA, USA). Peptides 
were eluted at a flow rate of 200 µL/min using the follow-
ing gradient of solvent B in solvent A: 3 % B for 3 min, 
3–30  % B in 32  min, 30–80  % B in 5  min, and 80–3  % 
B in 3  min. Solvent A was water containing 0.1  % (vol-
ume fraction) formic acid and solvent B was acetonitrile 
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containing 0.1  % formic acid. The acquisition method 
used the following parameters in positive mode: frag-
mentor 380 V, collision energy 25 V, cell accelerator 4 V, 
electron multiplier 600  V, and capillary voltage 3500  V. 
Selected transitions from fragmentation data and non-
linear retention time alignment from data-dependent 
MS analysis were used to confirm the retention time and 
identity during MRM analysis (Additional file  2: Table 
S2); the transition most appropriate for quantification 
for each peptide is listed in Table 1. MRM assay develop-
ment met applicable criteria for Tier 3 MRM assay [16].
Chromatographic peaks were integrated for transitions 
selected for quantification and peak areas for peptides 
were divided by the peak area of a non-modified pep-
tide for the respective histone (Table  1). Ratios of bio-
logical replicates and injection replicates were averaged 
and the average from the normal frontal cortex samples 
was used to normalize the normal group to 1.00 and to 
normalize the AD-affected group for easy comparison of 
fold changes. Student’s two-tailed t test was performed to 
determine the level of statistical significance of changes 
between AD and normal groups.
Results and discussion
Selection of transitions for MRM
Initially, histones were purified from normal and AD-
affected tissue to produce a sample with less complex 
matrix for improved identification of histone peptides in 
a discovery mode screening. While dynamic exclusion 
was used during MS acquisition, data-dependent analy-
sis benefits from having enrichment of the histone tar-
gets, particularly when a histone PTM may be only a few 
percent of the total amount of the unmodified peptide. 
Once peptides were identified by Mascot and MassMa-
trix and manually confirmed using retention time analy-
sis and spectra annotation, a transition list was created 
from abundant fragment ions, which was used for MRM. 
The optimized transitions used for quantification are in 
Table 1.
Preparation of samples
SDS was added to tissue homogenates at the very first 
step of sample processing to arrest enzymatic activity 
and minimize unwanted loss of PTMs. Early addition 
of SDS also efficiently denatures proteins and evenly 
exposes Cys residues in all samples for subsequent reduc-
tion and alkylation. A challenge to processing brain tis-
sue for MS analysis is its high lipid content, which can 
degrade chromatography performance and contribute 
to ion suppression. The whole brain is approximately 
80  % lipid by dry mass [17] and, therefore, necessitates 
removal of lipids. Chloroform/methanol precipitation 
of the protein efficiently removed lipids, SDS, salts, and 
by-products alkylation to yield a pure protein pellet. For 
PTM screening, histones were extensively purified. How-
ever, it was preferable to minimally process the tissue 
samples for quantification to evaluate differences in AD 
versus normal frontal cortex because extensive process-
ing may cause a loss in PTMs and also introduce process-
ing artifacts, resulting in inaccuracy of measurements 
[18, 19]. These two major steps, (1) early addition of SDS 
followed by reduction/alkylation of Cys residues and (2) 
chloroform/methanol precipitation to increase protein 
purity, ensure sample quality compatible with LC–MS/
MS analyses, while minimizing processing to maintain 
endogenous PTMs.
Table 1 Histone modifications and associated MRM transitions used for quantification
Modifications (ac) acetylation, (me) methylation, and (ub) ubiquitination of peptides were measured and normalized to an unmodified peptide, shown in italics, from 
the respective histone
Histone Sequence Precursor ion (m/z) Product ion (m/z)
H2A AGLQFPVGR 472.796 (2+) 703.39 (1+, y6)
H2A (canonical) VTIAQGGVLPNIQAVLLPK 966.08 (2+) 1092.68 (1+, y10)
H2A (1-A, 2-B, H2Ax) LLGGVTIAQGGVLPNIQAVLLPK 757.80 (3+) 546.84 (2+, y10)
H2B EIQTAVR 408.73 (2+) 446.27 (1+, y4)
H2B, K108-methylation LLLPGELAKme 484.31 (2+) 736.46 (1+, b7)
H2B, K120-ubiquitination AVTKubYTSSK 549.79 (2+) 827.43 (1+, y6)
H3 DIQLAR 358.21 (2+) 359.24 (1+, y3)
H3, K4-, K9-acetylation KacQLATKacAAR 535.82 (2+) 772.47 (1+, y7)
H4 VFLENVIR 495.29 (2+) 501.31 (1+, y4)
H4, K8-, K12-, K16-acetylation GGKacGLGKacGGAKacR 606.34 (2+) 927.54 (1+, y9)
H4, K12-, K16-acetylation GLGKacGGAKacR 464.27 (2+) 530.30 (1+, y5)
H4, R55-methylation ISGLIYEETRme 597.82 (2+) 290.18 (1+, y2)
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Reproducibility and data quality
Selected transitions for quantification had Gaussian 
peak shape with more than ten data points across each 
peak and suitable intensity as is preferred for quantifica-
tion (Additional file 3: Figure S1). However, it is impor-
tant to establish the level of variability in measurements 
to confirm that observed changes are attributed to true 
biological changes and not an artifact of LC–MS/MS 
performance or sample preparation. To demonstrate our 
data quality, we first performed six replicate injections 
of the same sample (Fig. 1a) and measured modified H3 
peptide KacQLATKacAAR as a ratio to non-modified H3 
peptide DIQLAR. Measured ratios were nearly identical 
with negligible variation (Fig.  1a), demonstrating LC–
MS/MS performance was precise and not a contributor 
to measurement variation. Second, we compared vari-
ability between six biological samples from normal fron-
tal cortex using the ratio of non-modified H2B peptide 
EIQTAVR to H3 peptide DIQLAR (Fig.  1b). Histones 
H2B and H3 are present in equal amounts as there is a 1:1 
stoichiometry between core histones in the nucleosome. 
Therefore, H2B to H3 should not change between donors 
or sample preparations. Indeed, our measurements con-
firm that there is negligible variation in H2B/H3 between 
donors, demonstrating that our sample preparation 
results in precision of measurements. Lastly, we moni-
tored the H3 peptide KacQLATKacAAR as a ratio to 
H3 peptide DIQLAR (Fig. 1c) for the same six donors of 
normal frontal cortex and in the same LC–MS/MS runs 
as for Fig.  1b. Detectable variability across donors for 
KacQLATKacAAR shows that variability in KacQLAT-
KacAAR measurements is due to biological differences in 
PTM level between donors. In summary, we established 
that measured differences between AD and control sam-
ples described herein are representative of biological var-
iation and that our sample preparation and MRM assay is 
robust and precise.
Effect of histone used for normalization
Changes in quantified histone PTMs between AD and 
normal frontal cortex from human donors are presented 
in Fig. 2b. For quantification of histone PTMs, the peak 
areas of modified peptides were normalized to the peak 
areas of non-modified peptides from the respective his-
tone. For example, ubiquitinated H2B peptide AVTKu-
bYTSSK was normalized to H2B peptide EIQTAVR while 
acetylated H4 peptide GLGKacGGAKacR was normal-
ized to H4 peptide VFLENVIR. While normalization of 
PTMs within a protein to the total amount of the pro-
tein is an accepted practice for quantification [20], it is 
Fig. 1 Variability in replicate measurements. a The ratio of modified 
H3 peptide KacQLATKacAAR to H3 was measured in six replicate 
injections of a frontal cortex sample from a normal donor and 
individual ratios were normalized to their average (n = 6) and plotted 
to show the negligible variability between replicate injections. b 
The ratio of non-modified H2B to H3 plotted for biological replicates 
from normal donors (n = 6) and normalized to the average, showing 
negligible variability between biological replicates for the stoichio-
metric H2B/H3 ratio. c The ratio of KacQLATKacAAR to H3 plotted for 
the average of two injections for each biological sample from normal 
donors (n = 6) and normalized to the average for all measurements 
(n = 12), showing variability in PTM is attributed to differences in 
donors and not due to inherent variability in MRM
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typically not advisable to normalize PTMs within one 
protein to the total abundance of a different protein. His-
tones, however, are present in a stoichiometric 1:1:1:1 
ratio of H2A:H2B:H3:H4 in the nucleosome. Due to their 
equal abundance, using a peptide from a single histone 
for normalization of all measured histone PTMs should 
generate similar quantification results and relative stand-
ard deviation (RSD) without a bias for using the respec-
tive histone that contains the PTM for normalization. 
We performed a series of normalizations, normalizing all 
measured PTMs to a single histone to evaluate the effect 
of normalization (Fig.  2a). We were able to show that 
there is a close consensus in RSD between H2A, H2B, 
and H3 normalization. H4 normalization varied in RSD 
with H4 RSD matching that of the other histones or being 
more or less than that of the other histones used for nor-
malization. While H4 was often different than the con-
sensus RSD for other histones, it did not show bias for H4 
PTMs or PTMs of other histones. While the histone used 
for normalization should not have an effect, we would 
expect any effect on normalization to have a bias for nor-
malizing PTMs to their respective histone, resulting in 
lower RSD for H4 PTMs to total H4 pairs. Additionally, 
no single histone showed a significantly different RSD 
when used for normalization. The average RSD when 
PTMs were normalized to their respective histones was 
Fig. 2 Histone PTMs in frontal cortex. a Measured peak areas of each quantified peptide were normalized to the peak area of different histone 
subunits. The relative standard deviation (n = 12) for each quantified peptide in normal and AD frontal cortex is shown grouped by the histone 
in which the peptides are located. The identity of the PTM measurements is presented in the graph in b, which appears in the same order. b 
Changes in histone PTMs in AD-affected human frontal cortex. Measurements were performed using human frontal cortex from normal (n = 6) 
and AD-affected (n = 6) donors (Additional file 1: Table S1) and two experimental replicates per donor (n = 12 total measurements per condition). 
Q-peptide transitions are summarized in Table 1. Data presented as mean ± SD. PTMs are (ac) acetylation, (me) methylation, and (ub) ubquitination. 
*p < 0.05; **p < 0.01; ***p < 0.001
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19 %, while normalizing all PTMs to one histone yielded 
an average RSD of 19 % for H2A, 20 % for H2B, 19 % for 
H3, and 22 % for H4. Overall, we were not able to observe 
any bias in histone normalization, which supports the 
stoichiometric relationship of histones in the nucleosome 
and the quality of our normalized measurements.
Implications of histone PTMs in AD‑affected human frontal 
cortex
Observed changes in histone PTMs in AD are presented 
in Fig. 2b. In most sequence variants, histone H2A con-
tains a lysine or arginine residue at position 99, however 
variants 1-A, 2-B, and H2Ax do not contain K/R99. Since 
K/R99 is a potential site for modification, the inability to 
regulate by K/R99 via a reduction in variants that con-
tain this site could be of importance. We did not observe 
any differences in abundance in isoforms with K/R99 or 
without K/R99, indicating turnover of these variants is 
not present in AD pathology in the frontal cortex. Simi-
larly, measurements for K4- and K9-acetylated H3 and 
K8-, K12-, and K16-acetylated H4 did not show statisti-
cally significant changes between AD and control. We did 
measure significant changes in PTMs of other sites that 
are associated with structural and functional implications 
related to AD.
K12- and K16-acetylated H4 increased 25 % in AD. The 
increase in K12- and K16-acetylated H4 could be due to a 
loss in acetylation of K8, leading to tryptic cleavage after 
K8 and increasing the peptide 9GLGKacGGAKacR17. 
While we did not observe a change in 6GGKacGLGKacG-
GAKacR17, loss of K5 acetylation may have increased 
fragment 6–17, which was simultaneously undergoing a 
loss of K8 acetylation, resulting in no net change in frag-
ment 6–17. Global deaceylation of histones is associated 
with AD; however, our data suggests that deacetylation 
may be occurring more frequently at the N-terminus of 
the histone tail. The N-terminal regions of histones are 
rich in glycine residues, which provide a high degree of 
flexibility to histone tails and lack of tertiary structure. 
Additionally, the high abundance of basic residues lysine 
and arginine contribute to an overall positive charge. 
Positively charged histone tails and negatively charged 
DNA form an electrostatic interaction that structurally 
results in the tail region wrapping along the DNA back-
bone, thereby forming a tight nucleosome structure [21]. 
The reduction in net charge, due to the DNA-histone tail 
interaction, and orientation of the extended tail against 
the nucleosome surface lead to denser, less transcription-
ally active chromatin [21]. The loss of N-terminal acetyla-
tion induces this charge interaction and likely results in 
decreased gene expression in the AD frontal cortex. Dea-
cetylation of histones is catalyzed by histone deacetylases 
(HDACs) and there is a growing interest in using HDAC 
inhibitors to slow aberrant deacetylation in brain [22]. 
Our previous work measured absolute concentrations of 
HDAC isoforms and identified specific isoforms associ-
ated with AD pathology in various neural tissues [4].
While HDAC has demonstrated potential as a pro-
spective AD therapy, therapies targeting other histone-
modifying enzymes have yet to come forward. Other 
PTMs, such as methylation, are modulated by enzymes 
with greater residue specificity than acetyltransferases 
and deacetylases. Often times, a methyltransferase or 
demethylase may only act on one site in a histone [23]. 
This specificity may correlate to improved efficacy and 
safety when targeting enzymes for specific methylation 
sites compared to HDAC inhibition alone. Additionally, 
they may be more efficacious as a combinatorial treat-
ment. H2B methylation at K108 decreased 25 % and H4 
methylation at R55 decreased 35  % in AD frontal cor-
tex (Fig.  2b). Both of these sites have been reported to 
be methylated in human cells [24]. To our knowledge, 
H2B K108 and H4 R55 methylation have not been inves-
tigated in AD-affected human frontal cortex. Both H2B 
K108 and H4 R55 are located on the outermost surface 
of the nucleosome (Fig. 3a) [25], suggesting their acces-
sibility to methyltransferases and demethylases may 
incline them to be used as switches for transcriptional 
activity. Monomethylation is commonly a marker of 
transcription activation. Since AD is characterized by 
a global repression in gene expression, our observed 
decrease in several methylation sites strongly suggests 
their role in reducing transcription consistent with AD. 
H4 R55 participates in a complex hydrogen bond net-
work in the nucleosome (Fig. 3b) [25]. H4 residues Q27 
and E52 and the I29 backbone form a hydrogen bond 
network that structurally thrusts N25 into a hydrogen 
bond with E73 on neighboring histone H3 [26]. By form-
ing a hydrogen bonding network that increases affinity 
between H3 and H4, the nucleosome becomes struc-
turally more stable. However, methylation of H4 R55 
likely disrupts this bonding network, thereby lessening 
the H3–H4 interaction and weakening the nucleosome 
[26]. Our observed decrease in methylation of R55 may 
be a mechanism for increasing nucleosome stability 
and favoring denser chromatin, which decreases gene 
expression. Similarly, H2B K108 is central to a hydro-
gen bond network involving histones H2A, H2B, and H4 
(Fig.  3c) [25]. H2B K108 and E105 participate in intra-
chain hydrogen bonding which structurally positions 
H2B residues for two interactions between neighboring 
histones favoring nucleosome stability. First, K108 forms 
a hydrogen bond with E105, pulling E105 away from 
close proximity to E93 on histone H2A. E105 and E93 
can create electrostatic repulsion, however when E105 
is distanced from E93 and hydrogen bonded to K108, 
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this electrostatic repulsion is greatly reduced and H2A 
and H2B are able nestle together [25]. Second, the K108 
hydrogen bond with E105 twists the helix-loop-helix, 
shown in Fig.  3c, to position R99 on H2B directly fac-
ing T71 on H4 for a hydrogen bond. This hydrogen bond 
between residues on H2B and H4 strengthen the H2B–
H4 stability. Methylation likely disturbs this H4–H2B–
H2A inter-chain network and would favor disassembly 
of the nucleosome. The structural and functional effect 
of our observed decrease in methylation of H2B K108 
is consistent with the decrease in H4 R55, suggesting 
methylation of histones is used to down regulate tran-
scriptional activity and gene expression in AD pathology. 
Establishing specific sites of histone methylation and 
their modulation, as described herein, is important in 
characterizing AD pathology.
H2B ubiquitination at K120 increased 91  % in AD 
(Fig. 2b). K120 has been reported to be ubiquitinated in 
human cell culture and animal neural tissue [11, 24, 27], 
but we were unable to find reports measuring ubiqui-
tination of this site in AD-affected human frontal cor-
tex. Polyubiquitination of proteins is commonly to mark 
proteins for degradation; however, monoubiquitination 
of proteins is typically used for regulatory functions [8]. 
After trypsin digestion, a di-glycine remnant of ubiq-
uitination remains on modified lysine residues, which 
does not allow for differentiation between mono- and 
polyubiquitination. Polyubiquitination of histones is less 
common, but has been suggested to affect the affinity of 
histone–histone interactions within the nucleosome [7]. 
Monoubiquitination of histones has been shown to indi-
cate the presence of DNA damage [8, 9] and to engage 
in “cross-talk” with methylation of other sites [27]. Ubiq-
uitination of H2B K120 has been shown to be inversely 
related to methylation of H3 core residue K79 [27]. While 
we did not detect methylation of H3 K79, we did detect 
a decrease in methylation of other core residues H2B 
K108 and H4 R55. Additionally, site H2B K120 is an eas-
ily accessible site for ubiquitin ligases as it is located on 
the outermost surface of the nucleosome core and distant 
from the histone–DNA interface (Fig. 3a) [25], an impor-
tant consideration for a relatively large, 8.5  kDa PTM. 
Abnormal accumulation of ubiquitinated proteins other 
than histones in AD has been reported [28], suggesting 
ubiquitination in AD may extend beyond histones and 
the epigenome.
Fig. 3 Location of core PTMs on nucleosome surface. H2A (blue), H2B (pink), H3 (yellow), and H4 (green) form an octamer in the nucleosome core, 
which is wrapped by DNA. Nucleosome crystal structure PDB ID: 2CV5 [25] was modified using PyMOL Molecular Graphics System (Version 1.7.2, 
Schrödinger, LLC). a Methylation sites R55 on H4 and K108 on H3 and ubiquitination site K121 on H2B are shown in red. b Hydrogen bond network 
of H4 R55. c Hydrogen bond network of H2B K108
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Conclusion
Histone PTMs have been implicated in many biologi-
cal functions and diseases and serve an important role 
in epigenetic regulation of gene expression. Aberrant 
modulations in histone PTMs have been suggested to 
occur in brain as part of AD pathology. Histone PTMs 
that were found to be significantly different in AD frontal 
cortex were decreases in methylation of H2B K108 and 
H4 R55 and an increase in ubiquitination of H2B K120. 
Changes of these sites have not been previously reported 
in AD-affected frontal cortex in humans. Additionally, 
acetylated H4 peptide 9GLGKacGGAKacR17 increased 
in abundance, which may indicate N-terminal loss of 
acetylation of K5 and K8. Structural effects induced by 
changes in these PTMs likely alter gene expression in the 
brain. Future work to evaluate the combinatorial effect of 
these PTMs on gene expression and other specific func-
tional roles may prove to be important in elucidating the 
pathology of AD. Moreover, the PTMs described herein 
could be used to identify specific histone-modifying 
enzymes to serve as drug targets for the treatment of AD, 
a disease which currently does not have any approved 
therapies to slow disease progression in humans. The 
etiology of AD is not known and the etiology may vary 
between individual cases of sporadic AD; however, epi-
genetic regulation is directly responsible for dysfunction 
in gene expression, which is consistently observed across 
AD individuals. Ideally, treatment at the earliest stage of 
disease pathology would be preferred, but the unknown 
and possibly diverse etiology strongly supports the phar-
maceutical intervention of a conserved component of AD 
pathology, namely histone PTMs.
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